Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc. (CRVS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Corvus is a clinical-stage biopharmaceutical company developing product candidates targeting immune cell maturation and function. The company has no approved products and has not generated any revenue from product sales. Its primary focus is on three clinical-stage candidates: soquelitinib (ITK inhibitor), ciforadenant (Adenosine A2A receptor antagonist), and mupadolimab (Anti-CD73 antibody).
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(15.3) million | $(62.3) million | $(27.0) million |
| Research & Development Expenses | $33.7 million | $19.4 million | $16.5 million |
| General & Administrative Expenses | $9.3 million | $8.2 million | $6.9 million |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $56.8 million | $51.6 million | N/A |
| Accumulated Deficit (Dec 31, 2025) | $(412.3) million | $(397.0) million | $(334.7) million |
| Net Cash Used in Operating Activities | $(32.8) million | $(25.4) million | $(23.9) million |
Note: The 2025 net loss was significantly reduced by a $27.1 million gain from the change in fair value of warrant liability. In 2024, a $33.4 million loss from the same item increased the net loss.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased from $62.3 million in 2024 to $15.3 million in 2025. This improvement was primarily driven by a $27.1 million non-cash gain related to the change in fair value of warrant liability, offsetting increased operating expenses.
- Increased R&D Spend: Research and development expenses increased by $14.3 million (74%) year-over-year, primarily due to increased clinical trial expenses ($6.0 million) and drug manufacturing costs ($4.8 million) for the lead candidate, soquelitinib.
- Warrant Liability Resolution: As of December 31, 2025, all common warrants issued in May 2024 were exercised, resulting in $54.3 million in proceeds and eliminating the warrant liability balance that existed at the end of 2024 ($28.9 million).
- Equity Method Investment: The loss from the equity method investment (Angel Pharmaceuticals) decreased to $2.0 million in 2025 from $3.2 million in 2024.
Guidance, Outlook, and Risks
Clinical Pipeline Progress
- Soquelitinib (ITK Inhibitor):
- T-Cell Lymphoma: A registrational Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma (PTCL) was initiated in Q3 2024. The FDA has granted Fast Track and Orphan Drug Designations.
- Atopic Dermatitis: Positive results were announced in January 2026 from Cohort 4 of the Phase 1 trial. A Phase 2 trial is planned to initiate in Q1 2026.
- Ciforadenant: Enrollment in the Phase 1b/2 trial for metastatic renal cell carcinoma (in combination with ipilimumab and nivolumab) has been completed.
- Mupadolimab: Development is currently paused to prioritize soquelitinib and ciforadenant.
Liquidity and Capital Resources
As of December 31, 2025, the company held $56.8 million in cash and marketable securities. On January 23, 2026 (subsequent event), Corvus completed a follow-on public offering raising approximately $189.4 million in net proceeds. Management expects these resources to fund operations into the second quarter of 2028. The company anticipates needing additional financing to complete all development programs through commercialization.
Key Risks
- Need for Additional Capital: The company has incurred significant losses since inception and expects to continue doing so. Failure to secure additional financing could force delays or termination of product development.
- Clinical Trial Uncertainty: Product candidates are in various stages of development and may fail to demonstrate safety or efficacy in later-stage trials.
- Regulatory Approval: No products are currently approved. Regulatory approval is not guaranteed and depends on successful clinical outcomes.
- Third-Party Reliance: The company relies on third parties for manufacturing and clinical trial conduct.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $189.4 million raised in January 2026 combined with existing cash to fund the Phase 3 PTCL trial and the new Phase 2 Atopic Dermatitis trial through 2028.
- Soquelitinib Phase 3 Enrollment: Monitor the enrollment rate and interim data for the registrational Phase 3 trial in PTCL, which is the primary near-term value driver.
- Atopic Dermatitis Phase 2 Design: Review the specific design and endpoints of the Phase 2 trial planned for Q1 2026 to assess the path to commercialization in dermatology.
- Warrant Exercise Impact: Confirm the dilution impact from the January 2026 offering and the prior exercise of warrants in 2025.
- Angel Pharmaceuticals Status: Monitor the financial health and development progress of Angel Pharmaceuticals (49.7% owned), which holds rights to Corvus's pipeline in Greater China.